Pharma Quality Control Merck to Acquire Rapid Micro Biosystems

Source: Press release Merck 2 min Reading Time

Related Vendors

Under a definitive agreement, Merck will take over Rapid Micro Biosystems, a firm that provides instruments, consumables, software and services for automating microbial quality-control testing in pharmaceutical manufacturing.

Under the terms of the agreement, Merck would acquire Rapid Micro Biosystems for 0.75 dollars per share in cash.(Source:  Merck)
Under the terms of the agreement, Merck would acquire Rapid Micro Biosystems for 0.75 dollars per share in cash.
(Source: Merck)

Darmstadt/Germany – Merck has signed a definitive agreement to acquire Rapid Micro Biosystems. Rapid Micro Biosystems provides instruments, consumables, software and services that automate microbial quality-control testing in pharmaceutical manufacturing. The proposed acquisition would advance Merck’s strategic focus on integrated workflows by bringing Rapid Micro Biosystems’ Growth Direct platform together with its complementary pharmaceutical quality-control portfolio.

Under the terms of the agreement, Merck would acquire Rapid Micro Biosystems for 0.75 dollars per share in cash.

“Quality control is essential to the reliable manufacture of medicines,” said Paolo Carli, Head of Advanced Solutions for the Life Science business of Merck. “Our customers need reliable results faster, more efficient quality-control workflows and robust data integrity to support regulatory compliance. Rapid Micro Biosystems will strengthen our ability to meet those needs, building on our existing offering and bringing greater automation to a critical step in pharmaceutical manufacturing.”

Rapid Micro Biosystems’ Growth Direct platform fully automates microbial quality control testing to include sample incubation, imaging and colony counting. Pharmaceutical manufacturers rely on Growth Direct to automate environmental monitoring, water and bioburden testing.

By detecting microbial growth during incubation, the system is designed to provide results meaningfully faster than conventional manual methods and helps quality-control teams make decisions earlier. The platform also digitizes sample tracking and results, reducing manual transcription and supporting data integrity.

Stay up to Date

Do you want the latest news, specialist articles and information on new products? Then you can register for our free newsletter:

Choose your Newsletter

As the development and manufacture of biologics and advanced therapies – including cell and gene therapies – grow more complex, quality-control laboratories face greater demand for consistent testing, timely information and connected data. Automation can help laboratories manage these demands by reducing the time to results, minimizing manual steps and supporting earlier decisions.

The proposed acquisition would build on the portfolio of pharmaceutical quality-control products and workflow solutions in Merck’s Life Science business sector, spanning environmental monitoring, in-process testing and release testing. Rapid Micro Biosystems’ automated microbial detection and data-management capabilities would strengthen this offering, supporting Merck’s increased focus on integrated workflow solutions as part of its mid- to long-term strategic agenda.

The proposed acquisition builds on the companies’ global distribution and collaboration agreement announced in February 2025.

“Joining Merck will give us the opportunity to combine our expertise in automation with a broader range of quality-control workflow solutions,” said Robert Spignesi, President and CEO of Rapid Micro Biosystems. “Our collective capabilities and deep understanding of pharmaceutical manufacturing and quality control will enable us to more fully serve our combined global customer base.”

The transaction is expected to close in December 2026, subject to customary closing conditions, including the tender of a number of voting shares of Rapid Micro Biosystems that represents at least a majority of the outstanding voting shares of Rapid Micro Biosystems (including shares issued upon exercise of pre-funded warrants).

(ID:51023943)

Subscribe to the newsletter now

Don't Miss out on Our Best Content

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy. The consent declaration relates, among other things, to the sending of editorial newsletters by email and to data matching for marketing purposes with selected advertising partners (e.g., LinkedIn, Google, Meta).

Unfold for details of your consent